M&A definitely a possibility for this little Aussie start up....

M&A definitely a possibility for this little Aussie start up. US$1bn starting price would be nice.

Accelerate R&D. Pharma companies acquiring biotech assets can reduce the projected timeline for assets in the pipeline by at least 30 percent, on average. Success requires R&D integration that taps the power of the acquirer’s R&D system while preserving the target’s unique capabilities.
https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life#

Deloitte report;

With big pharma continuing to face loss of exclusivity events across various therapeutic areas, we believe 2024 will be another strong year for big pharma to plug portfolio gaps through M&A.

https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html